Tap William D, Federman Noah, Eilber Fritz C
UCLA Sarcoma Program, Division of Hematology/Oncology, Los Angeles, CA 90095-7059, USA.
Expert Rev Anticancer Ther. 2007 May;7(5):725-33. doi: 10.1586/14737140.7.5.725.
The past several decades have revealed certain challenges that are inherent to soft-tissue sarcomas with regards to devising, testing and setting treatment paradigms for such a rare and heterogeneous malignancy. Despite this, significant advances have been made through the efforts of scientists, clinicians and patients alike. We are now entering a molecular era of cancer and current biotechnology is beginning to unravel the pathogenic enigma of these often devastating tumors. As our understanding of these malignancies improves, so does our list of potential treatment options. The impetus now lies with the medical/scientific community to direct translational research and subsequently the development and clinical testing of novel compounds in a fashion that best serves this unique patient population. To do so, we must continue to integrate the lessons of the past with the resources and promise of the future. This review will outline current areas of therapeutic interest in soft-tissue sarcomas with regard to agents that have reached clinical testing.
在过去几十年中，软组织肉瘤在设计、测试和确定针对这种罕见且异质性恶性肿瘤的治疗模式方面存在一些固有挑战。尽管如此，通过科学家、临床医生和患者的共同努力，已经取得了重大进展。我们现在正进入癌症的分子时代，当前的生物技术开始揭开这些通常具有毁灭性肿瘤的致病之谜。随着我们对这些恶性肿瘤的认识不断提高，潜在治疗选择的清单也在增加。现在，推动转化研究以及随后以最适合这一独特患者群体的方式开发和临床试验新型化合物的动力在于医学/科学界。为此，我们必须继续将过去的经验教训与未来的资源和希望相结合。本综述将概述目前在软组织肉瘤治疗方面对已进入临床试验阶段的药物感兴趣的领域。
